BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...

Political uncertainty has created buying opportunities among blue-chip healthcare stocks with big-time dividends.

BridgeBio Pharma Inc. gained US approval for a drug to treat a progressive and deadly form of heart disease, paving the way ...

Anthropic announced it received an additional $4 billion investment from Amazon as they deepened their partnership with AWS ...

U.S. Sen. Ron Johnson has threatened to issue a subpoena when he becomes chairman of the Permanent Subcommittee on ...

A COVID-19 study in Britain looked at the medical records of 1.7 million children but did not conclude the same number of ...

Fewer than 18% of U.S. adults have opted to receive the newly updated COVID-19 vaccine, according to the latest data from the ...

Pfizer shares are trading lower by 10% in November. President-elect Donald Trump last week announced his intention to nominate Robert F. Kennedy Jr. to lead the HHS.

For Big Pharma, recent headlines out of China suggest multinational drugmakers are facing their share of challenges in the ...

GLP-1 RAs to assist with weight loss have exploded in popularity. Researchers are working to identify which patients will ...

Wolfe Research has recently initiated Pfizer Inc (PFE) stock to Underperform rating, as announced on November 15, 2024, according to Finviz. Earlier, on October 25, 2024, Citigroup had resumed the ...

Pfizer has found a successor for retiring Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the ...